MarketPeel
Insider Trading Intelligence
Pricing
…
DL

Dennis M. Lanfear

CHRS
PRESIDENT & CEO · COHERUS ONCOLOGY, INC. · CIK 0001420822
FILING MIX · LIFETIME55%/45%
BUYS
27
SELLS
22
TOTAL VALUE
$2.04M
COMPANIES
1
ACTIVE SINCE
Jan 2020
HOLDINGS NOW
0
AVG SELL PX
$4.28
TRADE KIND
SHOWING 49 / 49
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizons
Forward-return performance of every backtestable P/S trade by Dennis M. Lanfear, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+0.00%+6.03%+0.22%+5.81%+5.81%—
14d2+0.00%+12.29%+0.23%+12.06%+12.06%—
30d2+50.00%-0.48%+3.45%-3.93%-3.93%—
60d2+50.00%+11.91%+5.91%+6.00%+6.00%—
90d2+0.00%+19.75%+8.44%+11.31%+11.31%—
180d2+0.00%+16.50%+13.34%+3.16%+3.16%—
1y2+100.00%-44.28%+15.45%-59.74%-59.74%—
2y2+100.00%-51.40%+26.22%-77.62%-77.62%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
CHRS · 0 shares · as of May 29, 2026
0262,059524,118786,1761,048,235202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 27 buys / 22 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
CHRS
COHERUS ONCOLOGY, INC.
SALE
President & CEO
125,000——0May 29, 2026Jun 2, 2026 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
450,000——450,000May 29, 2026Jun 2, 2026 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
225,000——225,000May 29, 2026Jun 2, 2026 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
President & CEO
402,500——0May 29, 2026Jun 2, 2026 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
President & CEO
225,000——0May 29, 2026Jun 2, 2026 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
500,000——500,000May 29, 2026Jun 2, 2026 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
402,500——402,500May 29, 2026Jun 2, 2026 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
President & CEO
200,000——0May 29, 2026Jun 2, 2026 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
President & CEO
450,000——0May 29, 2026Jun 2, 2026 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
200,000——200,000May 29, 2026Jun 2, 2026 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
President & CEO
400,000——0May 29, 2026Jun 2, 2026 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
400,000——400,000May 29, 2026Jun 2, 2026 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
125,000——125,000May 29, 2026Jun 2, 2026 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
President & CEO
500,000——0May 29, 2026Jun 2, 2026 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
375,000——1,048,235Jan 23, 2026Jan 26, 2026 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
750,000——750,000Jan 23, 2026Jan 26, 2026 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
President & CEO
11,839$1.55$18.4K673,235Jan 20, 2026Jan 22, 2026 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
375,000——375,000May 7, 2025May 9, 2025 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
President & CEO
11,810$1.39$16.4K685,074Jan 20, 2025Jan 22, 2025 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
575,000——575,000Jan 10, 2025Jan 14, 2025 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
President & CEO
11,810$1.66$19.6K696,884Jan 4, 2025Jan 7, 2025 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
196,500——196,500Jul 22, 2024Jul 24, 2024 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
President & CEO
11,218$2.44$27.4K708,694Jan 20, 2024Jan 23, 2024 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
575,000——575,000Jan 5, 2024Jan 8, 2024 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
President & CEO
11,781$2.92$34.4K719,912Jan 4, 2024Jan 8, 2024 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASE
President & CEO
41,000$1.42$58.1K695,853Nov 22, 2023Nov 24, 2023 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASE
President & CEO
258,940$1.42$366.9K954,793Nov 22, 2023Nov 24, 2023 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
President & CEO
299,940——0Nov 22, 2023Nov 24, 2023 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
President & CEO
223,100$2.02$449.8K731,693Nov 22, 2023Nov 24, 2023 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
225,000——225,000Jun 13, 2023Jun 15, 2023 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
86,250——654,853Jan 20, 2023Jan 24, 2023 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
402,500——402,500Jan 5, 2023Jan 6, 2023 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
President & CEO
10,905$9.87$107.6K568,603Jan 4, 2023Jan 6, 2023 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALEGRANT
Gift
4,000——432,684Dec 30, 2022Jan 4, 2023 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
86,250——579,508Jan 4, 2022Jan 6, 2022 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
402,500——402,500Jan 4, 2022Jan 6, 2022 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALEGRANT
Gift
10,000——436,684Nov 17, 2021Nov 23, 2021 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
President & CEO
31,054——0Jun 8, 2021Jun 8, 2021 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASE
President & CEO
31,054$0.42$12.9K524,312Jun 8, 2021Jun 8, 2021 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
President & CEO
31,054$13.56$421.2K493,258Jun 8, 2021Jun 8, 2021 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASE
President & CEO
300,000$0.42$125.0K493,258Jun 6, 2021Jun 8, 2021 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
President & CEO
300,000——31,054Jun 6, 2021Jun 8, 2021 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
125,000——125,000Feb 1, 2021Feb 3, 2021 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
500,000——500,000Jan 23, 2021Jan 26, 2021 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASE
President & CEO
29,994$0.01$249193,258Jul 1, 2020Jul 6, 2020 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
President & CEO
29,994——0Jul 1, 2020Jul 6, 2020 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
500,000——500,000Jan 10, 2020Jan 14, 2020 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
59,763——184,780Jan 10, 2020Jan 14, 2020 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
President & CEO
21,516$17.73$381.5K163,264Jan 10, 2020Jan 14, 2020 ↗View →
Other insiders · CHRS
Loading peer insiders…
About this filer
CIK 0001420822
ROLE
President & CEO
PRIMARY
CHRS
COMPANIES
1
ACTIVE SINCE
Jan 2020
MARKETPEEL · /INSIDER/0001420822DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback